ArticleBMC cancer2026
Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
background and purposeThis study evaluated the incidence and clinical impact of radiation pneumonitis (RP) in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab following concurrent chemoradiotherapy (CCRT), with a particular focus on durvalumab interruption, re-administration, and overall survival (OS). MATERIALS AND
methodsThis retrospective study included patients treated at our institution between April 2018 and June 2024. Durvalumab was administered for up to one year or until discontinuation due to adverse events or disease progression. RP was graded according to CTCAE version 5.0. Associations between grade ≥ 2 RP and clinical or treatment-related factors were assessed using univariate and multivariate analyses. Survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazards models.
resultsAmong 101 patients, 48 (47.5%) developed grade ≥ 2 RP (grade 2: 41.6%; grade 3: 4.0%; grade 4: 2.0%). Lung V20 > 30% was independently associated with grade ≥ 2 RP. Durvalumab interruption occurred in a subset of patients with grade 2 RP; among these patients, 25 (59.5%) were able to undergo durvalumab re-administration, with RP recurrence observed in only one patient after re-administration. The 2-year and 3-year OS rates were 75.1% and 60.9%, respectively. Completion of durvalumab was the strongest independent predictor of OS (hazard ratio 0.14; P = 0.00007), whereas grade ≥ 2 RP itself was not significantly associated with OS.
conclusionsIn this real-world cohort, completion of durvalumab consolidation after CCRT was strongly associated with improved OS in patients with stage III NSCLC. Although grade ≥ 2 RP was a frequent complication, temporary interruption and re-administration were feasible in selected patients. However, these findings should be interpreted cautiously because of the retrospective design and potential residual confounding.
Indexed as
Identifiers
42919171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.